An early resiliency intervention program achieved measurable reductions in depression, anxiety and post-traumatic stress among individuals with acute neurologic illness who had been hospitalized in the intensive care unit, and their caregivers.
Intravenous Ketamine Clinic
Jackson Building, 1st floor
55 Fruit Street
Boston, MA 02114
Ketamine IV appointments are conducted in the Intravenous Ketamine Clinic on the Mass General main campus on Tuesday and Thursday evenings from 5:30 pm-8:30 pm.
Referring clinicians should fill out the referral form so we can determine whether the program is a good fit for the individual and gather relevant clinical information. A completed referral form is required prior to treatment.
Please send completed referral forms to firstname.lastname@example.org.
Explore This Treatment Program
The Intravenous Ketamine Clinic for Depression at Massachusetts General Hospital combines advanced psychopharmacology expertise with knowledge stemming from a decade of ketamine research. We offer treatment for patients with severe and refractory depression using the medication ketamine given through intravenous infusion or through the nose (intranasal). We work collaboratively with the outpatient treatment team to develop an appropriate plan for each patient.
As a part of the Depression Clinical and Research Program at Mass General, we are committed to advancing our knowledge and ability to treat depression by integrating clinical care and innovative research. We do this through a number of avenues:
- Our consultation services
- The ketamine intravenous (IV) infusion service and intranasal ketamine clinic
- Research studies focused on ketamine treatment
After a thorough consultation process, we offer IV infusions and intranasal ketamine maintenance to patients with severe depression or chronic suicidal ideation.
Ketamine treatment may be covered by your insurance, but to be sure please contact your insurer for updated information. The coverage of ketamine treatments is rapidly evolving at this time.
- “Randomized, double-blind ketamine augmentation in chronically suicidal, treatment-resistant major depression,” American Foundation for Suicide Prevention
- “New, rapidly-acting treatments for treatment-resistant depression (RAPID),” National Institute of Mental Health, PI Maurizio Fava, MD
- “Baseline insular dysfunction as a predictor of ketamine’s antidepressant effects in anxious depression,” NARSAD, Brain & Behavior Research Foundation
- Ionescu DF, Swee MB, Pavone KJ, Taylor N, Johnson-Akeju O, Baer L, Nyer M, Cassano P, Mischoulon D, Alpert JE, Brown EN, Nock MK, Fava M, Cusin C. “Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine.” Journal of Clinical Psychiatry. June 2016.
- Ionescu DF, Felicione JM, Gosai A, Cusin C, Shin S, Shapero BJ, Deckersbach T. “Ketamine-associated brain changes: A review of the neuroimaging literature." Harvard Review of Psychiatry. February 2018.
- Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, Trivedi M, Fava M. “Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.” Journal of Psychiatric Research. March 2019.
- Ketamine Non-Responders Exhibit Pathological Increases in Extracellular Free Water Following Treatment–New Evidence of Astrocyte Pathology in Depression. Peyda S, Sydnor VJ, Kubicki M, Karayumak SC, Cheung J, Felicione JM, Shenton ME, Akeju-Johnson O, Pasternak O, Deckersbach T, Cusin C. Annual Meeting of American Society Clinical Pathology, Miami, May 29-June 1, 2018
- Gender Differences in the Response to and Tolerability of Ketamine as a Treatment for Acute Depression. Freeman MP, Papakostas G, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, Trivedi M, Fava M. Annual Meeting of American Society Clinical Pathology, Miami, May 29-June 1, 2018
- Press Release
- Aug | 14 | 2020
Study of more than 100 modifiable factors for depression identifies social connection as the strongest protective factor
Researchers from Massachusetts General Hospital (MGH) have identified a set of modifiable factors from a field of over 100 that could represent valuable targets for preventing depression in adults.
- Mar | 13 | 2020
A new study shows that ketamine is effective in treating some patients with treatment-resistant depression. The fast-acting drug is effective both in patients with anxiety and in those without it.
- Patient Education
- Feb | 3 | 2020
Learn how doctors diagnose and treat depression in children.
- Patient Education
- Jan | 7 | 2020
In this Q&A, learn more about how depression affects children and how you can help your child from Mai Uchida, MD, director of Early Identification and Prevention of Pediatric Depression and provider in Child and Adolescent Psychiatry at MassGeneral Hospital for Children (MGHfC).
- Press Release
- Dec | 17 | 2019
A team of researchers is among the first to ask if baby teeth can be used to explore if there are certain ages when being exposed to childhood adversity is even more harmful.
Pioneering Psychiatry Research
The integration of patient care and clinical research has been a hallmark of the Department of Psychiatry for more than 30 years. Today, the department has the largest clinical research program in the hospital, with studies at the forefront of neuroscience, molecular biology and genetics.